FILE - A sign for Eli Lilly & Co. sits outside their corporate headquarters in Indianapolis on April 26, 2017. A closely watched Alzheimer's drug from Eli Lilly won the backing of federal health advisers on Monday, June 10, 2024, setting the stage for the treatment's expected approval for people with mild dementia caused by the brain-robbing disease. (AP Photo/Darron Cummings, File)



A highly anticipated Alzheimer's medication by Eli Lilly received approval from federal health advisors on Monday, paving the way for its expected clearance to treat mild dementia caused by the disease. 

The drug, donanemab, demonstrated the potential to slow down the progression of Alzheimer's, with FDA advisors unanimously agreeing that its benefits outweighed its risks, including side effects like brain swelling and bleeding. Panel member Dean Follmann, a statistician from the National Institutes of Health, expressed confidence in the drug's effectiveness based on trial evidence.

 The FDA will have the final say on its approval later this year, and if greenlit, donanemab would be only the second Alzheimer's drug in the U.S. proven to effectively slow cognitive decline and memory loss caused by the disease. The FDA previously approved a similar infused drug, Leqembi, from Eisai in 2023. While both medications demonstrated a modest delay in cognitive decline among patients with early-stage Alzheimer's, there were questions raised regarding Lilly's approach to studying donanemab.

 Lilly's use of tau protein levels to group patients led to concerns about whether tau screening via brain scans would be necessary before administering the drug. However, most panelists concluded that there was sufficient evidence of the drug's benefits to warrant broader prescription without such screening. 

Additionally, Lilly's strategy of discontinuing treatment for patients with low levels of amyloid, a key contributor to Alzheimer's, was met with some skepticism from FDA staff due to insufficient data supporting the optimal timing for stopping treatment. Nonetheless, many panelists saw potential benefits in this approach, citing potential cost savings and reduced side effects. 

The main safety concern associated with donanemab was brain swelling and bleeding, although most cases observed during Lilly's trial were mild. The panel agreed that these risks could be managed through warning labels, physician education, and medical scans to identify patients at higher risk of stroke. Despite the uncertainties surrounding Lilly's testing methods, the FDA panel's endorsement marks a significant step forward in the development of Alzheimer's treatments.

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

You may also like

Alberta Health Issues Measles Alert for Southern Region, Including Calgary

Alberta Health Services (AHS) has released a public health notice following a recent spike in confirmed measles cases in southern....

U.S. Pushes to Remove Artificial Dyes from Foods by 2026

In a move aimed at improving children’s health, U.S. health officials announced plans to eliminate artificial food dyes from the....

Pandemic Delays in Cancer Screenings Show Minimal Long-Term Impact, Study finds

A new report reveals that delays in cancer screenings during the early days of the COVID-19 pandemic may not have....

‘Ice Bucket Challenge’ Reimagined, Viral Trend Turned into Mental Health Movement

The iconic Ice Bucket Challenge is back — but this time, with a powerful new purpose. Students at the University....

Wyoming Abortion Bans Head to State Supreme Court for Review

Wyoming’s abortion laws are once again under legal scrutiny. On Wednesday, the state Supreme Court will hear arguments over controversial....

Measles Outbreak Grows Amid Confusion Over Vaccine Messaging

The United States is grappling with a major measles outbreak, but experts say poor communication and mixed messaging about vaccines....

Toronto's UHN Launches Strategic Global Recruitment For Top Medical Scientists Amid U.S. Cuts Jobs

Toronto’s University Health Network (UHN), Canada’s leading research hospital, has unveiled an ambitious global recruitment strategy aimed at positioning the....

Shingles Vaccine May Lower Dementia Risk, Study Finds

Scientists have uncovered compelling evidence linking the shingles vaccine to a reduced risk of dementia. A large-scale study conducted in....

Fungal Infections becoming Resistant to Treatment, WHO Issues Urgent Warning

The World Health Organization (WHO) has raised alarms over drug-resistant fungal infections, warning that some treatments are no longer effective.....

Kennedy’s HHS Overhaul Puts Addiction Treatment At Risk

A major shakeup in the U.S. Department of Health and Human Services (HHS) could lead to the weakening—or even elimination—of....

Deadly Fungal Superbug Candida Auris Spreads Rapidly in Hospitals

A dangerous fungal superbug, Candida auris (C. auris), is rapidly spreading in hospitals and nursing homes, raising serious public health....

Researchers in Limbo as Columbia Caves to Trump’s Demands for $400M

Columbia University is facing intense scrutiny after agreeing to strict policy changes to regain $400 million in federal funding revoked....